IQVIA (IQV) Projected to Post Earnings on Tuesday

IQVIA (NYSE:IQV) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of $2.62 per share and revenue of $3.77 billion for the quarter. IQVIA has set its FY 2025 guidance at 11.700-12.100 EPS.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts expect IQVIA to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

IQVIA Stock Performance

IQV stock opened at $153.42 on Friday. IQVIA has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The company has a market capitalization of $27.05 billion, a P/E ratio of 20.46, a PEG ratio of 1.99 and a beta of 1.46. The company has a 50-day simple moving average of $167.52 and a 200 day simple moving average of $191.06. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on IQV shares. Citigroup cut their price target on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. JPMorgan Chase & Co. cut their price target on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Robert W. Baird cut their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. Finally, StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $237.62.

Hedge Funds Weigh In On IQVIA

A hedge fund recently raised its stake in IQVIA stock. Brighton Jones LLC grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 244.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,575 shares of the medical research company’s stock after purchasing an additional 2,537 shares during the quarter. Brighton Jones LLC’s holdings in IQVIA were worth $703,000 as of its most recent SEC filing. 89.62% of the stock is owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.